Millie
your market intelligence analyst
Search Results
227 results
Your search is now limited to «Bristol-Myers Squibb» expert search.
Bristol Myers Squibb receives EC approval for Zeposia in adults with RRMS with active disease.
More from Pharmaceutical Business Review:
Zacks.com 05/27/2020 11:50
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
More from Zacks.com:
Benzinga 05/27/2020 08:28
Click here for information about joining the class action] On November 20, 2019, BMS issued a press release announcing the completion of its merger with Celgene Corporation ("Celgene.
More from Benzinga:
Business Wire 05/27/2020 06:59
Celgene and Juno Therapeutics are wholly owned subsidiaries of Bristol-Myers Squibb Company.
More from Business Wire:
Reuters.com 05/26/2020 17:26
Bristol-Myers Squibb Co:
More from Reuters.com:
Investor's Business Daily 05/23/2020 08:00
Bristol Myers Stock Bristol-Myers stock tried to break out past a 63.28 handle buy point earlier this month.
More from Investor's Business Daily:
Forbes 05/20/2020 01:21
We don’t foresee any significant impact on Bristol-Myers Squibb’s business from the current crisis, and despite its outperformance, we believe Bristol-Myers Squibb’s valuation to be $81 per share – roughly 26% ahead of the current market price.
More from Forbes:
Seeking Alpha 05/19/2020 10:33
Bristol-Myers Squibb (BMY) certainly isn't as undervalued as it was only a few weeks ago.
More from Seeking Alpha:
Motley Fool 05/17/2020 14:03
Both Pfizer and BMS have seen their stocks plunge close to 30% this year then make strong rebounds.
More from Motley Fool:
Reuters.com 05/15/2020 15:32
FDA approves Bristol-Myers combo therapy for lung cancer.
More from Reuters.com:
Xconomy 05/15/2020 10:19
French firm Genfit reported a trial failure in an intensely competitive indication, and New York-based Bristol Myers Squibb encountered a delay when the FDA declined to review its experimental multiple myeloma treatment.
More from Xconomy:
BioPharma-Reporter 05/14/2020 07:59
In a blow to Bristol Myers Squibb and bluebird bio’s hopes to gain a speedy approval for ide-cel (idecabtagene vicleucel), the US Food and Drug Administration (FDA) issued a ‘refusal to file’ letter.
More from BioPharma-Reporter:
PharmaTimes 05/14/2020 04:45
US regulators have refused to file Bristol Myers Squibb and bluebird bio's marketing application seeking approval of idecabtagene vicleucel (ide-cel) for patients with heavily pre-treated relapsed and refractory multiple myeloma.
More from PharmaTimes:
Big News Network (UAE) 05/13/2020 22:55
Bristol cited a number of factors including acquisition and integration expenses for the Celgene Corp. acquisition, which closed in November.
More from Big News Network (UAE):
STAT 05/13/2020 08:27
FDA refuses application for cell therapy from Bristol and Bluebird, dealing both a major setback.
More from STAT:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications